| Date Filed | Type | Description |
| 09/26/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
4
| Wong Alvin F (Chief Scientific Officer) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 6,938 shares
@ $3.3112, valued at
$23k
|
|
| 07/06/2023 |
4
| NOUGUES MAXIMO F (CFO) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 14,680 shares
@ $3.3112, valued at
$48.6k
|
|
| 07/06/2023 |
4
| Ludwig Jeffrey Jerome (Chief Commercial Officer) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 12,103 shares
@ $3.3112, valued at
$40.1k
|
|
| 07/06/2023 |
4
| HUNT DOUGLAS M (See Remarks) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 7,809 shares
@ $3.3112, valued at
$25.9k
|
|
| 07/06/2023 |
4
| AUERBACH ALAN H (President and CEO) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 60,698 shares
@ $3.3112, valued at
$201k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/15/2023 |
4
| WILSON TROY EDWARD (Director) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 27,000 shares
@ $3.4544, valued at
$93.3k
Granted 27,000 shares
@ $0 |
|
| 06/15/2023 |
4
| MOYES JAY M (Director) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 22,000 shares
@ $3.4532, valued at
$76k
Granted 27,000 shares
@ $0 |
|
| 06/15/2023 |
4
| Stuglik Brian M (Director) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 9,900 shares
@ $3.4598, valued at
$34.3k
Granted 27,000 shares
@ $0 |
|
| 06/15/2023 |
4
| Senderowicz Adrian (Director) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 27,000 shares
@ $3.4548, valued at
$93.3k
Granted 27,000 shares
@ $0 |
|
| 06/15/2023 |
4
| Dorval Allison (Director) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 10,000 shares
@ $3.45, valued at
$34.5k
Granted 27,000 shares
@ $0 |
|
| 06/15/2023 |
4
| MILLER MICHAEL PATRICK (Director) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 13,500 shares
@ $3.4541, valued at
$46.6k
Granted 27,000 shares
@ $0 |
|
| 06/15/2023 |
4
| Cesano Alessandra (Director) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Granted 27,000 shares
@ $0 |
|
| 06/15/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/06/2023 |
4
| Wong Alvin F (Chief Scientific Officer) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Sold 269 shares
@ $3.4498, valued at
$928 |
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
4
| Wong Alvin F (Chief Scientific Officer) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Granted 58,601 shares
@ $0
Granted 81,399 options to buy
@ $4.39, valued at
$357.3k
|
|
| 02/14/2023 |
4
| NOUGUES MAXIMO F (CFO) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Granted 58,601 shares
@ $0
Granted 81,399 options to buy
@ $4.39, valued at
$357.3k
|
|
| 02/14/2023 |
4
| Ludwig Jeffrey Jerome (Chief Commercial Officer) has filed a Form 4 on PUMA BIOTECHNOLOGY, INC.|
Txns:
| Granted 66,972 shares
@ $0
Granted 93,028 options to buy
@ $4.39, valued at
$408.4k
|
|
|